Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii
Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal
central nervous system infection in patients with AIDS. Untreated, the encephalitis is
fatal. The best treatment for this disease has not been determined. Presently it is standard
practice to administer a combination of pyrimethamine and sulfadiazine. Little is known
about the pharmacokinetics of pyrimethamine in patients with AIDS receiving AZT.
Furthermore, there are reports that patients already exposed to toxoplasmosis may not have
uniform absorption of pyrimethamine.
Patients receive the study treatment for a total of 22 days. Patients are given an initial
dose of pyrimethamine followed by a lower dose given as a single oral daily dose for 21
days. Patients continue to receive AZT at the dose prescribed prior to enrollment in the
study. Patients receive leucovorin calcium once a day. Neither the leucovorin calcium nor
the AZT are provided through the study.
Endpoint Classification: Pharmacokinetics Study, Masking: Open Label, Primary Purpose: Treatment
United States: Federal Government
|Memorial Sloan-Kettering Cancer Ctr.||New York, New York 10021|
|Unc Aids Crs||Chapel Hill, North Carolina 27599|